{"name":"Grifols Therapeutics LLC","slug":"grifols-therapeutics-llc","ticker":"","exchange":"","domain":"grifolsllc.com","description":"Grifols Therapeutics LLC is a leading plasma-derived protein therapies company, dedicated to improving the health and well-being of patients worldwide through its extensive portfolio of life-saving medicines. With a strong focus on innovation and quality, Grifols continues to expand its therapeutic offerings in areas such as immunology and critical care.","hq":"Sant Cugat del Vallès","founded":0,"employees":"N/A","ceo":"Nacho Abia","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Alphanate","genericName":"Alphanate","slug":"alphanate","indication":"Other","status":"discontinued"},{"name":"Diphtheria-Tetanus Toxoids Adsorbed","genericName":"Diphtheria-Tetanus Toxoids Adsorbed","slug":"diphtheria-tetanus-toxoids-adsorbed","indication":"Other","status":"marketed"},{"name":"Xembify","genericName":"Xembify","slug":"xembify","indication":"Other","status":"marketed"},{"name":"Albutein 20%","genericName":"Albutein 20%","slug":"albutein-20","indication":"Other","status":"phase_3"},{"name":"Alpha-1 MP","genericName":"Alpha-1 MP","slug":"alpha-1-mp","indication":"Other","status":"phase_3"},{"name":"GAMUNEX-C","genericName":"GAMUNEX-C","slug":"gamunex-c","indication":"Other","status":"marketed"},{"name":"IGSC 20%","genericName":"IGSC 20%","slug":"igsc-20","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"IGIV-C 10%","genericName":"IGIV-C 10%","slug":"igiv-c-10","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"IVIG-PEG","genericName":"IVIG-PEG","slug":"ivig-peg","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"Immune Globulin (Human)","genericName":"Immune Globulin (Human)","slug":"immune-globulin-human","indication":"Primary immunodeficiency disorders","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Prolastin-C","genericName":"Prolastin-C","slug":"prolastin-c","indication":"Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease (COPD)","status":"marketed"}]}],"pipeline":[{"name":"Alphanate","genericName":"Alphanate","slug":"alphanate","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Diphtheria-Tetanus Toxoids Adsorbed","genericName":"Diphtheria-Tetanus Toxoids Adsorbed","slug":"diphtheria-tetanus-toxoids-adsorbed","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Xembify","genericName":"Xembify","slug":"xembify","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Albutein 20%","genericName":"Albutein 20%","slug":"albutein-20","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alpha-1 MP","genericName":"Alpha-1 MP","slug":"alpha-1-mp","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GAMUNEX-C","genericName":"GAMUNEX-C","slug":"gamunex-c","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IGIV-C 10%","genericName":"IGIV-C 10%","slug":"igiv-c-10","phase":"phase_3","mechanism":"IGIV-C 10% is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by supplying pooled human antibodies to modulate immune responses.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency conditions","Autoimmune and inflammatory disorders"],"catalyst":""},{"name":"IGSC 20%","genericName":"IGSC 20%","slug":"igsc-20","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IVIG-PEG","genericName":"IVIG-PEG","slug":"ivig-peg","phase":"phase_3","mechanism":"IVIG-PEG is a polyethylene glycol-conjugated intravenous immunoglobulin that provides passive immune protection by delivering pooled human antibodies with extended half-life.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency conditions"],"catalyst":""},{"name":"Immune Globulin (Human)","genericName":"Immune Globulin (Human)","slug":"immune-globulin-human","phase":"marketed","mechanism":"Immune Globulin (Human) provides passive immunization by supplying pooled human antibodies to enhance immune function and neutralize pathogens.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Chronic inflammatory demyelinating polyneuropathy (CIDP)","Immune thrombocytopenia (ITP)","Post-transfusion purpura"],"catalyst":""},{"name":"Prolastin-C","genericName":"Prolastin-C","slug":"prolastin-c","phase":"marketed","mechanism":"Prolastin-C is a purified human alpha-1 protease inhibitor (AAT) that replaces deficient or dysfunctional alpha-1 antitrypsin to protect lung tissue from enzymatic degradation.","indications":["Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease (COPD)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxOdmJtTy1PVXBHWGpWQ0dlM1otWU01LWJUZ0MtM0ZpRklNbW44d1BBdTR4WlRvdXViT1NTNW5VTlFKSXZoRTJSYkJadHVoTFh0R0lNQnV2VEtaUnptVmxYeWhkNU0tUldGRHdxSUh6YWd2ZWdWMzBrbVR6QVgwd0NlRV91MGY4aUdwR1lpMXJfcnJLQnp1eUF4UW5LaDBzcHdoZWxOdnlKeVE4M3ZpZ3k2czdmTjh3UUxnX2FXZ2dGNm5YTzJJVEtPUTNuZUxQLWRLWmtOTUpKMklFd29GU25xUVNWMTNGdkljeTJVdEJvdi1TTTBXWDFTWW0tRi1hNkFEbm56dUp5ZTV3Mm96bmFXZ1dFVWZ2Qk12UVpZR09B?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOX0VvS0JHbER2V2QzZExQSEFaTGRpdVBDa1VDek5yc3AweVdiWnBXTDhlVmlJTkFFU3V1M21STGtwa29zeGxOR3ZXeG0yQlhrOFg1ODdZMUNoRzBFdFYwcGJzRVlHdk1LXzhmMlFkNXJsRTN3VGdFSjJtdGdUYnJlb045bzlYZHRYbjljWk5GZlhPRlY3dHJ0MlB4NThTNUlyZC1fQnhqb1JVX252am9oT1htNFliTWNIdnc?oc=5","date":"2026-03-24","type":"regulatory","source":"Reuters","summary":"Grifols approves IPO of its US biopharma business - Reuters","headline":"Grifols approves IPO of its US biopharma business","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOVllrQVlCUFpmOGU2OVEtZVN4SFRUMWRkc2FNNElBZ1hhUk1GTW5ZUG9BTExaSnJNWEVQODFvUkQ0aFMybThDa2gtZ3haR1lUbzNMX0ZnYnAwVThOMC14QTZBOHN1YTQ2QlBicXNIaER6NkJzZ0ZmNjF1bzEzX2Zqck1zWlV3dk9MRDZRU2UtZ3NELW8?oc=5","date":"2026-03-24","type":"pipeline","source":"openPR.com","summary":"Hemophilia A Treatment Market (2026) | Advanced Biologics, - openPR.com","headline":"Hemophilia A Treatment Market (2026) | Advanced Biologics,","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"pipeline","source":"simplywall.st","summary":"Grifols (BME:GRF) Valuation Check After Recent Share Price Weakness - simplywall.st","headline":"Grifols (BME:GRF) Valuation Check After Recent Share Price Weakness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNNXBUV0xERXFESWN2Y0Y5ckVqM2hLemxRakFFVnZnTW1ESTRfLVZiRUgxb2lxUlo1VzNDU1REbnRpWVdNak1scmh0bldHR2hzd0F0TjdHeldRcE52R2syXzVmbGQ5RnVfVUVteTlZV3JJZWNreTNUS0ZPd2hWajZNbVFsMTRTc1ZTYTYxa1pidE5BOGRwLUFZU3IyTVNzSkE?oc=5","date":"2026-01-15","type":"pipeline","source":"The Business Journals","summary":"Prime land near pharma giants sold for $1 million - The Business Journals","headline":"Prime land near pharma giants sold for $1 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBMS3hqUFpsdlYxdFdZWldHZjhoU0g0Yklkc2YyOWhVSno5dlZXQXhHaGFUZGRJT09ITnczM1lITldNeUdVUnVuR3BES1JvYWZlVjAtdlgzMjBiOVBTVmhrTXk5aVpUdzlmYVFJSkt3?oc=5","date":"2025-08-11","type":"trial","source":"The HIPAA Journal","summary":"Cencora & The Lash Group Settle Data Breach Litigation for $40 Million - The HIPAA Journal","headline":"Cencora & The Lash Group Settle Data Breach Litigation for $40 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5IQmUzenFyWVNRbWlVVjRpS1VuSm5FcFRzdkJMQm4xVFM3ekU4Vmd6Y3RmTW5KbVNaYXBaM0ItRWdMN18wbU91eHJicXlCOWdhMHZDUUNSRU5hS1pRbVpKNVpCdmtyR2c3?oc=5","date":"2025-07-24","type":"trial","source":"Wiley Online Library","summary":"Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies - Wil","headline":"Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQc1c1d25oR2hwN3VOY2JmOHlPOE1ramlTdENfWlNqSzhhblNSZHpzbngxcXJlUE44WGFHeXd4UHBLVzh6d2xORHUxZ3U4VFhzRmI0aFo0d2ZhZl9QRHQ5ejhGV05wVG5TeFJpNk5rUWlaQi1QOXNPNnFDdUdGalFiVThDNVZjX01nQ1l6TUxncHAwclVfUHk3Njc5aGhhSy0xS1pucXNqaEFxS25mZWg4MV8tNzg3RHJOM2M0bHh4NFFMZEFrQl9nZjNnRW9ZYnM1U193QVJOMnVRLXptbnJILVRZcjZVOEx6SzMw?oc=5","date":"2025-05-30","type":"pipeline","source":"Reuters","summary":"US court proceeds with Grifols defamation case against Gotham City, but narrows scope - Reuters","headline":"US court proceeds with Grifols defamation case against Gotham City, but narrows scope","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQeUNSWE9fYUNjbWRjWlljaWp4cWdWd1A4c2hzRGt3MkhkTlVWRC0waEtKeFFhenlXVVcyY25HdVkyaDB2MTVNNVJDQ0tPSkNra2I5cmZzMjNzTlk0WWtZaTRYMjZ3RzhReUFUVmRkOVhha2NIRVhObzFHQVFCYW56dUtIanNpSnV3aThOX1BGQ1BSQ1RKbDVKQ1dERmxsYjAzYmgtSFNxTkpqcWxJ?oc=5","date":"2025-04-05","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com","headline":"Pharma 50: The top pharma companies in the world for 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaENlQ1VENWItVXRWTmpwZ251dW1QT0U2ZkVHTUdITlRWWl9TeDZta19JSl9KT2R0d29xTUM5dkpSUFdyZ1gyNFByTktCTHVWMTVaZUNJYkM3emZhTTlfZ0oxMlZneFI1ZGl2T0U5V1EteWZKUnFfUDVNd3FaWjVCX1RRMW10MG51Z1RmOWU5VHFyLVdqeXVWX19UWUpUSnVYT2dEcHphYnlvTmxabFlfaGwtekRkTU1qdHpF?oc=5","date":"2025-01-14","type":"pipeline","source":"Fierce Biotech","summary":"Grifols garners $21M grant from Michael J. Fox Foundation to hunt for early Parkinson's disease biomarkers - Fierce Biotech","headline":"Grifols garners $21M grant from Michael J. Fox Foundation to hunt for early Parkinson's disease biomarkers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPOXduWVp5b19OWFd5R1BzMkZvcldONC0xVEc3NTh1aEhJLU5HV1Q0Ni0zZlVxUGFzemZoRzBWdmVPOUJ0eXVnZVdKeGtQVTlQMmJNdEwzaWptc2puZTg2dFM5Vkk1XzlUX3R6bjllTTRVeGhzcGlzVTdkNXk0amx3bS1HWUY1UHdWOFlCNnhqS2ZlLVVhRmdHQWhDV3VncVRDcUlpUnU5b204Q3BEazN3bXRBclJZdDByMjQxNDZCX3RIWG9UVWc3YlV6Uk9UWGUyeGUyUmhlbEV0ZjVfYlJmbGVYMDR5YXBFeXAw?oc=5","date":"2023-07-12","type":"pipeline","source":"PR Newswire","summary":"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire","headline":"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"discontinued":1,"marketed":6,"phase_3":4},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}